0 0
    • Mark all read All chats All chats
    Finabase
    • Categories
    • Register
    • Login
    • Watchlists
    • Portfolios
    • Map
    • Forex
    • Futures
    • Crypto
    • Comparisons
    • Alerts
    • Screeners
    • Backtests
    • vTrading
    • Settings
    1. Home
    2. BCRX
    • Alert
    • Note
    BCRX
    BioCryst Pharmaceuticals, Inc.
    7.92
    +
    0.01
    0.13%
    2 x 7.92
    8 x 7.98
    bid
    ask
    5 @ 04:00 PM
    7.90-0.02 (0.25%)
    Bearish 31
    Bullish 78
    sentiment
    7.89
    day range
    8.01
    4.03
    52 week range
    8.88
    04:00 PM
    V: 1.31M
    C: 7.92
    L: 7.89
    H: 8.01
    O: 7.99
    loading chart ...
    • 1d
    • 5d
    • 1m
    • 3m
    • 6m
    • ytd
    • 1y
    • 2y
    • 5y
    • max
    • PDF
    • Full Chart
    • Stats
    • Watchlist
    • Portfolio
    Prev Close7.91
    Open7.99
    Low7.89
    High8.01
    Volume1.31M
    Avg. Volume2.62M
    Market Cap1.64B
    Inst. Own86.61%
    Beta1.88
    Short Ratio10.27
    Div & Yield0.00 /
    EPS-0.73
    P/E0.00
    1yr Target14.45
    50day MA7.62
    200day MA6.14
    ^DJI
    Dow Jones Industrial Average
    41606.20
    04:20 PM
    -
    15.90
    0.04%
    ^IXIC
    NASDAQ Composite
    17628.10
    04:51 PM
    +
    36.00
    0.20%
    ^GSPC
    S&P 500
    5634.58
    04:20 PM
    +
    1.49
    0.03%
    AAPL
    216.60
    -0.19 (0.09%)
    Apple Inc.
    216.79
    3 @ 04:00 PM
    2 x 216.27
    4 x 216.60
    +
    0.47
    0.22%
    GOOG
    160.40
    +0.12 (0.07%)
    Alphabet Inc.
    160.28
    9 @ 04:00 PM
    8 x 159.68
    9 x 159.92
    +
    1.29
    0.81%
    AMZN
    186.98
    +0.10 (0.05%)
    Amazon.com, Inc.
    186.88
    2 @ 04:00 PM
    1 x 186.64
    3 x 186.89
    +
    1.99
    1.08%
    MSFT
    435.85
    +0.70 (0.16%)
    Microsoft Corporation
    435.15
    1 @ 04:00 PM
    1 x 434.12
    1 x 434.67
    +
    3.81
    0.88%
    BABA
    84.52
    -0.19 (0.22%)
    Alibaba Group Holding Limited
    84.70
    9 @ 04:00 PM
    8 x 84.52
    10 x 84.83
    +
    1.10
    1.32%
    NFLX
    707.02
    +0.11 (0.02%)
    Netflix, Inc.
    706.91
    1 @ 04:00 PM
    1 x 704.05
    1 x 705.58
    +
    10.41
    1.49%
    TSLA
    227.77
    -0.10 (0.04%)
    Tesla, Inc.
    227.87
    3 @ 04:00 PM
    2 x 227.52
    3 x 228.26
    +
    1.09
    0.48%
    NVDA
    115.43
    -0.16 (0.14%)
    NVIDIA Corporation
    115.59
    1 @ 04:00 PM
    1 x 115.08
    1 x 115.42
    -
    1.19
    1.02%
    AMD
    150.67
    -0.15 (0.10%)
    Advanced Micro Devices, Inc.
    150.82
    2 @ 04:00 PM
    1 x 149.00
    3 x 150.06
    -
    1.26
    0.83%
    MU
    88.57
    -0.16 (0.18%)
    Micron Technology, Inc.
    88.73
    1 @ 04:00 PM
    1 x 88.33
    1 x 88.47
    +
    1.55
    1.78%
    SPY
    563.14
    +0.07 (0.01%)
    SPDR S&P 500 ETF Trust
    563.07
    9 @ 04:00 PM
    9 x 562.69
    8 x 562.99
    +
    0.23
    0.04%
    TQQQ
    66.56
    +0.07 (0.11%)
    ProShares UltraPro QQQ
    66.49
    9 @ 04:00 PM
    12 x 66.12
    5 x 66.14
    +
    0.04
    0.06%
    BRK-A
    Berkshire Hathaway Inc.
    685250.00
    04:00 PM
    10 x 682545.00
    11 x 683214.00
    +
    7519.00
    1.11%
    Day Gain
    Gain
    Market Val
    Costs
    Cash
    Portfolio
    Realized
    Dividend
    • Summary
    • Discussion
    • News
    • Signals
    • Financials
    • Alerts
    • Notes
    • Chart
    • Backtest
    News ...
    BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks globenewswire.com •
    Headlands Technologies LLC Acquires New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news.google.com •
    Principal Financial Group Inc. Has $220,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news.google.com •
    TD Asset Management Inc Makes New $1.49 Million Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news.google.com •
    Bank of New York Mellon Corp Has $4.80 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) news.google.com •
    BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Los Angeles Capital Management LLC news.google.com •
    Profile ...
    BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
    Earning ...
    Date For Estimate Reported Surprise surprise %
    2024-11-07 2024-09 -0.07 N/A N/A N/A
    2024-08-05 2024-06 -0.19 -0.06 0.13 68.42%
    2024-05-06 2024-03 -0.23 -0.17 0.06 26.09%
    2024-02-26 2023-12 -0.24 -0.28 -0.04 -16.67%
    2023-11-02 2023-09 -0.25 -0.19 0.06 24.00%
    2023-08-03 2023-06 -0.25 -0.24 0.01 4.00%
    Upgrade / Downgrade ...
    Date Firm Action From To
    2023-09-24 RBC Capital Upgrade Outperform Outperform
    2023-09-17 RBC Capital Upgrade Sector Perform Outperform
    2023-08-03 RBC Capital Upgrade Sector Perform Sector Perform
    2023-08-03 Jefferies Upgrade Hold Buy
    2023-08-03 HC Wainwright & Co. Upgrade Buy Buy
    2023-08-02 Needham Upgrade Buy
    Insider Holder ...
    Date Name Relation Quantity Description
    2024-06-11 ABERCROMBIE GEORGE B Director 36.43K Stock Award(Grant)
    2024-06-11 ASELAGE STEPHEN J Director 72.66K Stock Award(Grant)
    2024-06-11 GALSON STEVEN K Director 58.37K Stock Award(Grant)
    2024-06-13 HEGGIE THERESA Director 52.85K Sale
    2024-06-11 HUTSON NANCY J Director 93.64K Stock Award(Grant)
    2024-06-11 LEVIN ALAN G Director 51.77K Stock Award(Grant)
    Institution Ownership ...
    Report Date Organization Position Value Percentage
    2023-06-29 Blackrock Inc. 15.50M 109.09M 8.18%
    2023-06-29 Vanguard Group Inc 15.09M 106.23M 7.96%
    2023-06-29 Baker Brothers Advisors, LLC 12.71M 89.48M 6.71%
    2023-06-29 State Street Corporation 12.26M 86.34M 6.47%
    2023-06-29 Avoro Capital Advisors LLC 12.06M 84.87M 6.36%
    2023-06-29 Assenagon Asset Management S.A. 5.33M 37.54M 2.81%
    Fund Ownership ...
    Report Date Organization Position Value Percentage
    2023-08-30 SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF 8.22M 58.41M 4.34%
    2023-06-29 Vanguard Total Stock Market Index Fund 5.86M 41.26M 3.09%
    2023-08-30 iShares Russell 2000 ETF 4.29M 30.51M 2.26%
    2023-08-30 Fidelity Select Portfolios - Biotechnology 2.81M 19.96M 1.48%
    2023-06-29 Vanguard Extended Market Index Fund 2.58M 18.14M 1.36%
    2023-06-29 Vanguard Small-Cap Index Fund 2.44M 17.17M 1.29%
    Dividend ...
    Dividend Date
    0 2014-06-11
    0 2014-06-05
    0 2014-05-20
    0 2014-05-16
    0 2014-04-02
      • Oldest to Newest
      • Newest to Oldest
      • Most Votes
    • 1
    • 2
    • 3
    • 4
    • 5
    • 20
    • 21
    • 1 / 21
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 15 - last edited by
      #409

      @Vafa sorry my words connected. Can’t find edit here.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 15 - last edited by
      #410

      @Vafabbut when will that news hit be? The last news didn’t do anything imo.

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 15 - last edited by
      #411

      Company still selling shares at 4.50 target? They are still raising cash? How many shares do they have left to sell?

      1 Reply Last reply
      0
    • R Offline
      R Offline
      rncolucci | Only
      wrote on Jun 15 - last edited by
      #412

      Each new day ends in hope for the next day. Trying hard to remain positive, too many over paid shares to turn back now. Frustrated. Bought before the dilution.

      1 Reply Last reply
      0
    • A Offline
      A Offline
      ajnaser5 | Only
      wrote on May 18 - last edited by
      #413

      $TNXP
      $NBY
      Big news coming!! These 2 will rock soon!!

      1 Reply Last reply
      0
    • keith-al-dijailiK Offline
      keith-al-dijailiK Offline
      keith-al-dijaili | Only
      wrote on May 5 - last edited by
      #414

      HODL !!!!! Don’t Sell !

      1 Reply Last reply
      0
    • keith-al-dijailiK Offline
      keith-al-dijailiK Offline
      keith-al-dijaili | Only
      wrote on May 5 - last edited by
      #415

      We have take off !

      1 Reply Last reply
      0
    • keith-al-dijailiK Offline
      keith-al-dijailiK Offline
      keith-al-dijaili | Only
      wrote on May 5 - last edited by
      #416

      Blast off !!!

      1 Reply Last reply
      0
    • keith-al-dijailiK Offline
      keith-al-dijailiK Offline
      keith-al-dijaili | Only
      wrote on May 5 - last edited by
      #417

      https://www.google.com/amp/s/www.fool.com/amp/investing/general/2015/08/30/we-believe-healthcares-next-biotech-buyout-targe-2.aspx

      1 Reply Last reply
      0
    • keith-al-dijailiK Offline
      keith-al-dijailiK Offline
      keith-al-dijaili | Only
      wrote on May 5 - last edited by
      #418

      https://www.google.com/amp/s/www.fool.com/amp/investing/general/2015/08/30/we-believe-healthcares-next-biotech-buyout-targe-2.aspx

      1 Reply Last reply
      0
    • keith-al-dijailiK Offline
      keith-al-dijailiK Offline
      keith-al-dijaili | Only
      wrote on May 5 - last edited by
      #419

      Buy out coming soon !!! Get on board !

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 21 - last edited by
      #420

      $BCRX Some one tap the breakers slow this thing down

      1 Reply Last reply
      0
    • ahmed-abu-hamadA Offline
      ahmed-abu-hamadA Offline
      ahmed-abu-hamad | Only
      wrote on Apr 17 - last edited by
      #421

      CLOSELY watching BCRX exploded to 3.67 +1.08 now in pre mkt bull coil near 3.05 w SUPPOR /STOP under 2.90 DT to 3.35-.40 & 3.65 Maybe 4+

      1 Reply Last reply
      0
    • 1
    • 2
    • 3
    • 4
    • 5
    • 20
    • 21
    • 1 / 21

    • BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
      globenewswire.com •

    • Headlands Technologies LLC Acquires New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
      news.google.com •

    • Principal Financial Group Inc. Has $220,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
      news.google.com •

    • TD Asset Management Inc Makes New $1.49 Million Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
      news.google.com •

    • Bank of New York Mellon Corp Has $4.80 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
      news.google.com •

    • BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Los Angeles Capital Management LLC
      news.google.com •

    • Bank of New York Mellon Corp Has $4.80 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
      news.google.com •

    • BCRX- StockTitan
      news.google.com •

    • Are Biocryst Pharmaceuticals Inc.’shares a good deal?
      news.google.com •

    • Rice Hall James & Associates LLC Sells 71,904 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
      news.google.com •

    • Financial Health Report: Biocryst Pharmaceuticals Inc. (BCRX)’s Ratios Tell a Tale
      news.google.com •

    • BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
      globenewswire.com •

    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      globenewswire.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript
      seekingalpha.com •

    • Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?
      zacks.com •

    • BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
      zacks.com •

    • BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
      globenewswire.com •

    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      globenewswire.com •

    • 7 Small-Cap Stocks to Buy for Large-Scale Gains
      investorplace.com •

    • Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
      zacks.com •

    • BioCryst to Report Second Quarter 2024 Financial Results on August 5
      globenewswire.com •

    • Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
      seekingalpha.com •

    • BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
      zacks.com •

    • Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
      zacks.com •

    • ORLADEYO® (berotralstat) Approved in Peru
      globenewswire.com •

    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      globenewswire.com •

    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      globenewswire.com •

    • BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
      globenewswire.com •

    • BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
      globenewswire.com •

    • ORLADEYO® (berotralstat) Approved in Mexico
      globenewswire.com •

    • First post
      Last post
    0
    • Categories
    • Login
    • Don't have an account? Register
    • Login or register to search.
    Copyright © 2023 finabase.io